Ri­bon Ther­a­peu­tics rids pre­clin­i­cal work, trims staff to fo­cus on two clin­i­cal PARP in­hibitors

Ri­bon Ther­a­peu­tics, a biotech look­ing to make next-gen­er­a­tion oral PARP in­hibitors, has end­ed pre­clin­i­cal and plat­form work to fo­cus on two clin­i­cal pro­grams.

“Cuts across …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.